Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies

Maksim Mamonkin • 1 Sep 2020
EBMT 2020
Acute Lymphoblastic Leukemia Leukemia Lymphoma T-Cell Lymphoma Antibodies CAR-T
MAGENTA

Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, outlines the use of CD5 and CD7 directed CAR T-cells for pediatric T-cell malignancies, including the results of the first-in-man study of CD5 CAR T-cells in the treatment of T-cell malignancies, as well as challenges associated with bringing these innovative therapies to the clinic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Maksim Mamonkin

2:05
Using engineered T-cells to suppress acute GvHD and leukemia relapse after alloSCT
Maksim Mamonkin • 10 Feb 2023
1:51
CAR-T cell therapy for T-cell malignancies: challenges to address and future outlooks
Maksim Mamonkin • 10 Feb 2023
2:14
Exploring the potential role of CD7-targeting CAR-T cells for the treatment of T-ALL
Maksim Mamonkin • 10 Feb 2023
4:14
Resisting immune rejection: engineered off-the-shelf T-cells
Maksim Mamonkin • 20 Aug 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals